Maxim Group initiated coverage on TuHURA Biosciences with a new price target
$HURA
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/3/2025 | $13.00 | Buy | H.C. Wainwright |
| 12/19/2024 | $11.00 | Buy | Rodman & Renshaw |
| 11/5/2024 | $15.00 | Buy | Maxim Group |
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026 A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1 mutated relapsed/refractory AML Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as th
TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to an aggregate of 9,462,423 shares of its common stock and Series B warrants to purchase up to an aggregate of 9,462,423 shares of its common stock, at a purchase price of $1.65 per share and accompanying warrants in a registered direct offering. The warrants will have an exercise price of $1.95 per share
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced immunosuppression Data presented in the Company's poster demonstrated that the DOR is also expressed on tumor associated macrophages (TAMs) and DOR inhibition appears to reverse TAM mediated T cell suppression with the potential to overcome resistance to checkpoint inhibitor and other cancer immunotherapies TAMPA, Fla., Dec. 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 imm
H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00
Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00
Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
424B5 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing
Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026 A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1 mutated relapsed/refractory AML Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as th
Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)